The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The 27 greenfield labs across the country ensure timely and accurate reporting
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
This unit will focus on the manufacturing of health and wellness equipment
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Subscribe To Our Newsletter & Stay Updated
